![]() |
Name |
13,14,15,16-tetranorlabd-7-ene-19,6b:12,17-diolide
|
Molecular Formula | C17H22O3 | |
IUPAC Name* |
1,12-dimethyl-5-oxatetracyclo[7.6.1.02,7.012,16]hexadec-7-ene-4,11-dione
|
|
SMILES |
CC12CCCC3(C)C4CC(=O)OCC4=CC(CC1=O)C23
|
|
InChI |
InChI=1S/C17H22O3/c1-16-4-3-5-17(2)13(18)7-10(15(16)17)6-11-9-20-14(19)8-12(11)16/h6,10,12,15H,3-5,7-9H2,1-2H3/t10-,12-,15+,16+,17+/m0/s1
|
|
InChIKey |
MBQFBLICGWKOPD-OCNQBYMTSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 274.36 | ALogp: | 2.9 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 43.4 | Aromatic Rings: | 4 |
Heavy Atoms: | 20 | QED Weighted: | 0.5 |
Caco-2 Permeability: | -4.773 | MDCK Permeability: | 0.00002820 |
Pgp-inhibitor: | 0.943 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.024 |
30% Bioavailability (F30%): | 0.665 |
Blood-Brain-Barrier Penetration (BBB): | 0.921 | Plasma Protein Binding (PPB): | 62.62% |
Volume Distribution (VD): | 0.654 | Fu: | 37.05% |
CYP1A2-inhibitor: | 0.037 | CYP1A2-substrate: | 0.587 |
CYP2C19-inhibitor: | 0.323 | CYP2C19-substrate: | 0.87 |
CYP2C9-inhibitor: | 0.175 | CYP2C9-substrate: | 0.123 |
CYP2D6-inhibitor: | 0.024 | CYP2D6-substrate: | 0.318 |
CYP3A4-inhibitor: | 0.818 | CYP3A4-substrate: | 0.497 |
Clearance (CL): | 17.845 | Half-life (T1/2): | 0.417 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.07 |
Drug-inuced Liver Injury (DILI): | 0.428 | AMES Toxicity: | 0.053 |
Rat Oral Acute Toxicity: | 0.661 | Maximum Recommended Daily Dose: | 0.734 |
Skin Sensitization: | 0.07 | Carcinogencity: | 0.944 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.097 |
Respiratory Toxicity: | 0.952 |